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Abstract
The objective of this study is to describe briefly the burden of dyslipidemia, and to discuss and present
strategies for health professionals to improve dyslipidemia management, based on a review of selected literature
focusing on interventions for dyslipidemia treatment adherence. Despite the availability of effective lifestyle and
pharmaceutical therapies for dyslipidemias, they continue to present a significant economic burden in the United
States. Adherence to evidence-based guidelines for the treatment of dyslipidemias is unsatisfactory. The reasons
for medication nonadherence are complex and specific to each patient. The lack of progress in achieving optimal
lipid targets is caused by many factors: patient (medication adherence, cost of medication, literacy), medication
(adverse effects, complexity of regimen), provider (lack of adherence to evidence-based practice guidelines, poor
communication), and the US healthcare system (being focused on acute care rather than prevention, lack of
continuity of care, general lack of use of an electronic health record). Combined interventions that target each
part of the system have been effective in improving treatment adherence and achieving lipid goals. Patients,
providers, pharmacists, and employers all play a role in management of dyslipidemia. No single approach will
solve the complex issue of improving dyslipidemia management. The required lifestyle changes are known and
effective medications are available. The challenge is for all interested parties—including nurses, nurse practi-
tioners, doctors, pharmacists, other health care professionals, employers, and health plans—to help patients
achieve behavioral changes. (Population Health Management 2012;15:302–308)
Introduction
Dyslipidemias are associated with numerous medi-cal conditions including heart disease, peripheral
vascular disease, and stroke.1,2 The health and economic out-
comes associated with dyslipidemias are well documented. A
MEDLINE literature review in 2007 identified more than 43,000
papers about dyslipidemia, more than 700 of which focused on
its economic burden.3 Cardiovascular disease is responsible for
more than 800,000 deaths each year in the United States at an
estimated $286 billion in direct and indirect costs.4 About 16% of
the adult US population has a total cholesterol level ‡ 240 mg/
dL; 45% of adults have a total cholesterol level ‡ 200 mg/dL.4
The current guidelines for optimal cholesterol levels include:
low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL and
total cholesterol < 200 mg/dL.2 If patients are at very high risk
for coronary heart disease (CHD), an LDL-C goal of < 70 mg/
dL is recommended.5
The expert panel of the National Cholesterol Education
Program (NCEP) recommended initiating therapeutic life-
style changes if LDL-C is above goal and adding HMG-CoA
reductase inhibitor (statin) and other lipid-lowering medi-
cations for patients who have not achieved LDL-C treatment
goals through lifestyle modifications.2 Despite the estimate
that a 10% decrease in total cholesterol levels might reduce
the incidence of heart disease by 30%,6 less than half of those
who qualify receive lipid-lowering treatment for heart dis-
ease.2 Furthermore, the Healthcare Effectiveness Data and
Information Set (HEDIS) benchmarks for managed care
organizations (MCOs) include 2 measures for cholesterol
management. In 2009, 59.2% of commercially insured health
maintenance organization patients with a diagnosis of is-
chemic vascular disease had achieved LDL-C levels
< 100 mg/dL7; only 47.0% of patients with diabetes had
achieved LDL-C levels < 100 mg/dL.7
What role can health professionals play in achieving hy-
perlipidemia goals? A simulation study of the effects of
HEDIS performance measures on different health outcomes
found that if all MCOs met their hyperlipidemic targets at
the median level, approximately 1.9 million myocardial
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infarctions and 0.8 million strokes could have been pre-
vented over 10 years.8 Although the current review should
not be considered comprehensive of the entire body of lit-
erature surrounding dyslipidemia management, its purpose
is to discuss and present strategies for health management
professionals to help improve dyslipidemia care.
Strategies
Lifestyle changes
Several studies have demonstrated the benefits of diet and
exercise in reducing LDL-C and cardiovascular events in
patients with and without CHD.9–17 All adults should be
encouraged to adopt a healthy lifestyle, but these factors are
even more important for patients with elevated LDL-C lev-
els.5 These dietary and lifestyle modifications include
adopting healthy eating habits (limiting sugar and refined
carbohydrates, and increasing fruit, vegetable, and whole
grain consumption), not smoking, maintaining a healthy
weight and an optimal waist circumference, and engaging in
regular physical activity.2,18 If lifestyle modifications are
unsuccessful in achieving optimal lipid levels, lipid-lowering
therapy may be necessary.2,19
However, it appears that clinicians may be discounting the
benefits of lifestyle behavior changes prior to initiating
pharmaceutical treatment. In one study, 79% of study pa-
tients wanted to try changing their diet prior to starting a
statin but only half reported being given that opportunity.20
Of those who had the opportunity to modify their diet, 43%
felt they were not allowed sufficient time to change their
behavior before being prescribed a statin.20 Categorizing
patients based on risk factors into low, intermediate, and
high risk can provide physicians with guidelines about
which patients should attempt to make lifestyle changes
prior to initiating drug therapy.21
Pharmaceutical therapies
Although clinical trials repeatedly show that statins are
effective in lowering LDL-C levels,22–28 actual clinical expe-
rience does not always match these results.29–35 Medication
adherence, failure to titrate to the most effective dose or
medication, inadequate follow-up, disparities in screening
and prescribing, and lack of patient motivation all have been
hypothesized as reasons for the gap in achieving LDL-C
goals between what is reported in clinical trials and actual
results observed in physician medical practices.36–39
The NCEP has acknowledged5 that achieving the
< 70 mg/dL LDL-C goal will be difficult for many patients,
particularly using statin monotherapy.40 However, the effect
and risks of combining different types of cholesterol-lower-
ing medications (statins with bile acid sequestrants, or statins
with other lipid-lowering agents) is not well understood by
physicians,41 despite studies demonstrating their potential
safety and efficacy.42–46
The managed care community is familiar with the poor
medication adherence rates associated with many drug
classes and lipid-lowering therapies in particular.47 The
World Health Organization estimates an average medication
adherence rate of approximately 50%.48 Nonadherence is
associated with increased hospitalizations and treatment
costs as well as loss of productivity and premature death.49
Discontinuation rates among patients who initiate statin
therapy range from 15% to 78% depending on the study
location, sample demographics, and length of follow-up.50,51
Predictors of nonadherence
Studies have found that poor medication adherence is
associated with younger patient age, female sex, fewer co-
morbidities, no cholesterol level monitoring after statin
initiation, depression, low perceived risk of myocardial in-
farction, misconceptions about treatment duration,20,52 feel-
ings about medical providers and belief in the benefit of the
medication,53 number of other medications being taken,54
and prescription size.54,55 Higher co-payments also have
been found to be associated with lower levels of statin ad-
herence and prescription abandonment.52,56–60 Patients trea-
ted to a target cholesterol level are significantly more
adherent to statins and have better cardiovascular outcomes
than those treated by a ‘‘treat and forget’’ method.61
Suggestions for Population Health Management
How can health management professionals help to reduce
the burden of dyslipidemia among US adults? Is the lack of
progress in reducing LDL-C levels because of the patients
(medication adherence issues, cost of medication), the med-
ications (adverse effects, complexity of regimen), the pro-
viders (lack of evidence-based practice and follow-up, poor
communication), or the system (focused on acute care rather
than prevention, lack of continuity of care)?63–65 The Na-
tional Committee for Quality Assurance instituted a HEDIS
measure for MCOs that differentiates between the manage-
ment of individual patients (LCL-C goal < 100 mg/dL) and a
performance measure used to evaluate the care of a specific
population of patients who have had a major CHD event
(LDL-C goal < 70mg/dL).66 Researchers also have proposed
other measures that can help MCOs to benchmark their
quality of care of dyslipidemia. These include expanding the
population defined in HEDIS to include more candidates for
therapy, determining how many of those patients are on
lipid-lowering medications, and using the appropriate LDL-
C goal values from the NCEP recommendations.67
Providers
Providers must stay current on the most recent evidence-
based medicine guidelines for lipid management, such as the
identification of those patients at risk for cardiovascular
events and the use of appropriate lifestyle and medications
to achieve lipid treatment goals.68,69 Only about one third of
patients who receive treatment are achieving their LDL-C
goal, and fewer than 20% of CHD patients are at their target
LDL-C level.2 Results from other studies suggest that phy-
sicians are not titrating the dose of lipid-lowering medica-
tions to reach the optimal cholesterol goal.77,78 Providers
must be held to the most current evidence-based practice
guidelines for the appropriate use of statins, including cau-
tions, contraindications, and safety monitoring of various
parameters during treatment.71 Health care provider strate-
gies to improve adherence might include limiting the num-
ber of medications prescribed for a patient when possible.72
Earlier and more frequent follow-up visits also have
been shown to improve adherence to statins.73 In this regard,
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pay-for-performance initiatives have had some mixed but
promising results.74 Electronic medical records also show
promise in improving management of dyslipidemia.75,76
Nurses, nutritionists, and pharmacists can play an im-
portant role in a collaborative approach to dyslipidemia
management. Effective nutrition education can improve
blood lipid levels,77,78 while nurses and other members of the
health care team can provide effective case management
services to individuals, particularly those dealing with mul-
tiple risk factors for heart disease.79,80 Pharmacists are
knowledgeable about medications, treatment indications,
dosing, safety issues, side effects, and contraindications.
They are highly accessible at the point of medication dis-
pending and can improve medication adherence through
education and face-to-face counseling.81 In some cases,
pharmacist-managed clinics have been shown to improve
dyslipidemia management and goal attainment compared
with groups managed by primary care physicians.82–84
Patients
Patients also need better education that should include
addressing their individual health literacy. Those who are
knowledgeable and participate in their health care decisions
have better behaviors and outcomes.63 Cardiovascular pa-
tients have been shown not only to have poor adherence to
medication regimens and diet recommendations, but also
poor attendance at follow-up appointments.85 One large re-
view of statin adherence interventions found that, in general,
personalized and patient-focused interventions were the most
cost-effective.86 Research supports the use of techniques to
improve patients’ belief in their ability to follow medication
regimens.87 Moreover, patients who are made aware of the
potential adverse effects of medication may have appropriate
expectations and increased adherence.88 In one study, LDL-C,
exercise, and dietary goals were achieved by significantly
more patients who received nurse-mediated care compared to
patients who received only enhanced primary physician
care.8,9 Preactivating patients prior to physician visits may be
an important strategy. Written materials, telephone consulta-
tions, or pre-visit discussions with a care manager may enable
patients to be more assertive and involved in medical care
visits.63 Expecting all patient education and patient concerns
to be discussed in the traditional 15-minute physician visit is a
setup for failure.63 A technique called motivational inter-
viewing may help patients resolve any ambivalence they may
feel toward their prescribed treatment plan.90
Pill splitting has been promoted as a possible strategy to
improve patient adherence when medication cost is a barrier.91–95
Potential problems with pill splitting include inaccurate
dosing, loss of medication due to fragmentation, and patient
dissatisfaction, which could lead to nonadherence.91,96.97
Technology also may be used to improve adherence. The
Electronic Medication Management Assistant is a comput-
erized medication dispenser that patients can use at home.98
It works in conjunction with an electronic medication ad-
ministration record, which allows medication use to be su-
pervised remotely by health care providers who can take
action when the patient is nonadherent. Electronic caps, also
known as microelectronic monitoring systems (MEMS), have
been used in medication adherence research. Showing pa-
tients the results from their MEMS output and discussing the
results may be effective in increasing medication adher-
ence.99 A variety of other technologies are available to aid
with medication adherence, including smart phone remind-
ers, tracking applications, and videophone technology.
Pharmacy benefit managers
Organizations can work with their pharmacy benefit pro-
viders to ensure formulary access to the appropriate medi-
cations for dyslipidemia.68 These medications frequently have
higher co-pays because of the expense and widespread use of
statin drugs; however, it may be a cost-effective strategy in
terms of improved adherence and effectiveness to lower co-
payments for selected medications for certain patients.100,101
One study demonstrated that a co-payment reduction was
associated with a 7% improvement in statin adherence.102
Sokol and colleagues showed that the increased cost for
medication to treat dyslipidemia was more than offset
by the savings in health care cost from a reduction in hos-
pitalization expenditures that resulted from improved ad-
herence.103 Community-based studies utilizing pharmacists
to provide patient education have been successful in im-
proving medication adherence and clinical outcomes for
patients.104,105
Employers
Employers also have a vested interest in improving dys-
lipidemia management for their employees. One study found
that, even among executives for whom medication cost
should not be a barrier to medication adherence, only 68% of
statin users were adherent.106 Worksite disease management
programs commonly are used to improve the health and
productivity of employees. Compared with usual care, both
a worksite educational program and a small monetary in-
centive were successful in reducing LDL-C levels among
employees.107 As the frequent payers of health care costs,
employers can play an important role in benefit design and
selection of health plans that have proven to be better at
prevention-focused care. Pharmacy benefit plan design is an
important tool to improve patient treatment and adherence.
A literature review has indicated that as patient medication
cost sharing increases, there is a correlation with reduced
medication use but greater use of medical services, as well as
increased health consequences for conditions such as dysli-
pidemia.108
Conclusions
A Cochrane Collaboration reviewed interventions to
improve adherence to lipid-lowering medication.109 The re-
viewers concluded that adherence improvement interven-
tions typically fall into one of 4 categories: simplification of
drug regimen; patient information/education; intensified
patient care such as reminder programs; and complex be-
havioral interventions such as group sessions. Results from
the studies reviewed found that adherence rates changed
from - 3% to + 25% as a result of the interventions.109 A
combined intervention that targets both providers and pa-
tients also has been effective in increasing cholesterol goal
attainment (from 35.5% of patients before to 59.8% after the
intervention).110 There appears to be no single approach that
will solve the complex issue of improving dyslipidemia
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management. The required lifestyle changes are known and
effective medications are available. The challenge is for all
interested parties—nurses, physicians, pharmacists, em-
ployers, and health plans—to encourage patients to change
their behavior.
Advances in medical treatments will fail to realize their
potential in reducing chronic illness unless the system can
address the determinants of adherence. Access to medica-
tions is necessary but insufficient in itself for the successful
treatment of dyslipidemia and other conditions.48 The easiest
way to determine adherence may be for physicians to inquire
in a nonjudgmental manner about how many doses are
missed in the average week.65 Medication adherence has
been proposed as the ‘‘sixth vital sign’’ in addition to stan-
dard vital signs recorded on patient visits (ie, blood pressure,
pulse, respiration, temperature, and weight [or body mass
index]).40 Patients who have the most difficulty staying ad-
herent to their regimen—whether because of such factors as
cost, forgetfulness, misunderstanding of the benefits or side
effects, and number of pills—will benefit from the more in-
tensive interventions mentioned in this study, such as elec-
tronic monitoring with telephone reminders.
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